Literature DB >> 16545497

Synthesis and binding studies of epibatidine analogues as ligands for the nicotinic acetylcholine receptors.

Linjing Mu1, Konstantin Drandarov, William H Bisson, Anita Schibig, Christa Wirz, P August Schubiger, Gerrit Westera.   

Abstract

Neuronal nicotinic acetylcholine receptors (nAChRs) are transmembrane ligand-gated ion channels. Recent research demonstrated that selective nAChR ligands may have therapeutic potential in a number of CNS diseases and disorders. The alkaloid epibatidine is a highly potent non-opioid analgesic and nAChR agonist, but too toxic to be a useful ligand. To develop ligands selective for distinct nAChR subtypes and with reduced toxicity, a series of epibatidine and homoepibatidine analogues were synthesized. (+/-)-8-Methyl-3-(pyridin-3-yl)-8-azabicyclo[3,2,1]oct-2-ene, showed high affinity towards alpha4beta2 (Ki=2 nM), subtype selectivity (alpha4beta2/alpha7 affinity ratio>100) and relatively low toxicity in mice and can be labeled with 11C and 18F as positron emission tomography (PET) tracers for imaging of nAChRs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545497     DOI: 10.1016/j.ejmech.2006.01.015

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Evaluation of structurally diverse neuronal nicotinic receptor ligands for selectivity at the alpha6( *) subtype.

Authors:  Scott R Breining; Merouane Bencherif; Sharon R Grady; Paul Whiteaker; Michael J Marks; Charles R Wageman; Henry A Lester; Daniel Yohannes
Journal:  Bioorg Med Chem Lett       Date:  2009-05-27       Impact factor: 2.823

2.  Interactions between 2'-fluoro-(carbamoylpyridinyl)deschloroepibatidine analogues and acetylcholine-binding protein inform on potent antagonist activity against nicotinic receptors.

Authors:  Renata V Bueno; Samuel Davis; Alice Dawson; Pauline W Ondachi; F Ivy Carroll; William N Hunter
Journal:  Acta Crystallogr D Struct Biol       Date:  2022-02-21       Impact factor: 7.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.